Despite the widespread use of levothyroxine replacement therapy, a substantial proportion of patients continue to experience persistent symptoms and metabolic dysregulation even after achieving biochemical euthyroidism
IV therapy bypasses the gut, delivering nearly 100% bioavailability for faster, more noticeable results
Appetite suppression strengthens noticeably
This facilitates a very high absorption rate and, because it is fast-acting, it delivers efficient results immediately after finishing the treatment
The 12 mg dose produced 28.3% average body weight loss at 80 weeks, and a higher-BMI two-year subgroup reached 30.3% average loss at 104 weeks
Reduced GSH is widely expressed in plant, animal, and fungal cells (Wu et al., 2004)